Logo image of CABA

CABALETTA BIO INC (CABA) Stock Price, Quote, News and Overview

NASDAQ:CABA - Nasdaq - US12674W1099 - Common Stock - Currency: USD

1.87  +0.13 (+7.47%)

After market: 1.87 0 (0%)

CABA Quote, Performance and Key Statistics

CABALETTA BIO INC

NASDAQ:CABA (5/28/2025, 8:22:45 PM)

After market: 1.87 0 (0%)

1.87

+0.13 (+7.47%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High13.5
52 Week Low0.99
Market Cap94.88M
Shares50.74M
Float49.23M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/bmo
IPO10-25 2019-10-25


CABA short term performance overview.The bars show the price performance of CABA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

CABA long term performance overview.The bars show the price performance of CABA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 -60 -80

The current stock price of CABA is 1.87 USD. In the past month the price increased by 46.09%. In the past year, price decreased by -81.65%.

CABALETTA BIO INC / CABA Daily stock chart

CABA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.83 323.41B
AMGN AMGEN INC 13.41 149.70B
GILD GILEAD SCIENCES INC 14.01 134.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.30B
REGN REGENERON PHARMACEUTICALS 13.36 63.90B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.23B
ARGX ARGENX SE - ADR 98.17 35.18B
ONC BEIGENE LTD-ADR 6.16 25.99B
BNTX BIONTECH SE-ADR N/A 23.45B
NTRA NATERA INC N/A 22.01B
SMMT SUMMIT THERAPEUTICS INC N/A 19.34B
BIIB BIOGEN INC 8.06 18.69B

About CABA

Company Profile

CABA logo image Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 161 full-time employees. The company went IPO on 2019-10-25. The firm is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Company Info

CABALETTA BIO INC

2929 Arch Street, Suite 600

PHILADELPHIA PENNSYLVANIA 19104 US

CEO: Steven Nichtberger

Employees: 163

CABA Company Website

CABA Investor Relations

Phone: 12677593100

CABALETTA BIO INC / CABA FAQ

What is the stock price of CABALETTA BIO INC today?

The current stock price of CABA is 1.87 USD. The price increased by 7.47% in the last trading session.


What is the ticker symbol for CABALETTA BIO INC stock?

The exchange symbol of CABALETTA BIO INC is CABA and it is listed on the Nasdaq exchange.


On which exchange is CABA stock listed?

CABA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CABALETTA BIO INC stock?

17 analysts have analysed CABA and the average price target is 16.55 USD. This implies a price increase of 784.84% is expected in the next year compared to the current price of 1.87. Check the CABALETTA BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CABALETTA BIO INC worth?

CABALETTA BIO INC (CABA) has a market capitalization of 94.88M USD. This makes CABA a Micro Cap stock.


How many employees does CABALETTA BIO INC have?

CABALETTA BIO INC (CABA) currently has 163 employees.


What are the support and resistance levels for CABALETTA BIO INC (CABA) stock?

CABALETTA BIO INC (CABA) has a support level at 1.74 and a resistance level at 1.88. Check the full technical report for a detailed analysis of CABA support and resistance levels.


Should I buy CABALETTA BIO INC (CABA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CABALETTA BIO INC (CABA) stock pay dividends?

CABA does not pay a dividend.


When does CABALETTA BIO INC (CABA) report earnings?

CABALETTA BIO INC (CABA) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of CABALETTA BIO INC (CABA)?

CABALETTA BIO INC (CABA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.54).


What is the Short Interest ratio of CABALETTA BIO INC (CABA) stock?

The outstanding short interest for CABALETTA BIO INC (CABA) is 12.54% of its float. Check the ownership tab for more information on the CABA short interest.


CABA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CABA. When comparing the yearly performance of all stocks, CABA is a bad performer in the overall market: 91.89% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CABA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CABA. Both the profitability and financial health of CABA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CABA Financial Highlights

Over the last trailing twelve months CABA reported a non-GAAP Earnings per Share(EPS) of -2.54. The EPS decreased by -48.54% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -76.76%
ROE -104.28%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%-39.22%
Sales Q2Q%N/A
EPS 1Y (TTM)-48.54%
Revenue 1Y (TTM)N/A

CABA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to CABA. The Buy consensus is the average rating of analysts ratings from 17 analysts.


Ownership
Inst Owners79.53%
Ins Owners3.09%
Short Float %12.54%
Short Ratio7.51
Analysts
Analysts83.53
Price Target16.55 (785.03%)
EPS Next Y0.62%
Revenue Next YearN/A